Related Experiment Video
Updated: May 14, 2026
Regenerative Peripheral Nerve Interface: Surgical Protocol for a Randomized Controlled Trial in Postamputation Pain
Published on: March 15, 2024
Study protocol for a double-blinded randomized clinical trial evaluating effectiveness of neurodynamic approach in
Ambika Kormoker1, K M Amran Hossain1, Md Zahirul Islam2
1Department of Physiotherapy and Rehabilitation, Jashore University of Science and Technology (JUST), Jashore, Bangladesh.
Background:
Diabetic peripheral sensory neuropathy (DPSN) presents with pain or neuropathy symptoms and disturbances in lower limb sensory functions, leading to complicated diabetic foot conditions and declining quality of life. There is a research gap on the non-pharmacological conservative approach to this disabling condition. The objective of this study is to evaluate the effectiveness of the neurodynamic approach, along with electrophysical stimulation, in reducing the severity of neuropathic symptoms and improving the quality of life in patients with DPSN.
Methods:
An assessor and patient-blinded randomized clinical trial (RCT) on 90 DPSN cases through hospital-based simple random sampling. Participants will be randomly assigned equally to either the Neurodynamic approach or the Sham neurodynamic approach group by concealed allocation between April and August 2025 at the Nurul Islam Diabetic Center in Jashore, Bangladesh. The experimental group will receive the Neurodynamic approach, and the control group will receive the sham approach; however, both groups will receive transcutaneous electrical nerve stimulation (TENS) and home exercises for 12 sessions over 4 weeks. A pretest will be taken at baseline, a posttest after 4 weeks, and a follow-up evaluation after 12 weeks. In addition to outcome measures, manageable and fatal adverse events will be documented and reported.
Discussion:
This trial will be implemented in the non-pharmacological management of prevalent cases with DPSN and diabetic foot, sparing the burden of polypharmacy in people living with diabetes. Moreover, a positive result may guide clinicians toward an alternative in evidence-based practice, especially in a low-resource country like Bangladesh. This single-center trial may be limited by a lack of external generalizability, but it will lead to multicenter, large-sample studies in the future.
Trial Registration:
Registered from Clinical Trial Registry of India CTRI/2025/01/079801 [Registered on: 30/01/2025] Trial Registered Prospectively.
